Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.77 |
| ▸ | FGB | P02675 | 1/20 | 0.77 |
| ▸ | MMP14 | P50281 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | RAD52 | P43351 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | TERT | O14746 | 2/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32679354 | 0.95 | MAPT (0.77) | NSD2FGBMMP14MAPTMEN1 | |
| SCHEMBL6678121 | 0.95 | MAPT (0.77) | NSD2FGBMMP14MAPTMEN1 | |
| SCHEMBL375179 | 0.95 | NSD2 (0.70) | NSD2FGBMMP14MAPTMEN1 | |
| SCHEMBL9883949 | 0.92 | NSD2 (0.68) | NSD2FGBMMP14MAPTMEN1 | |
| SCHEMBL6665263 | 0.91 | MAPT (0.75) | NSD2FGBMMP14MAPTMEN1 | |
| SCHEMBL9357997 | 0.89 | NSD2 (0.77) | NSD2FGBMMP14MAPTMEN1 | |
| SCHEMBL31616918 | 0.89 | MAPT (0.73) | NSD2FGBMMP14MAPTMEN1 | |
| SCHEMBL12658875 | 0.89 | MAPT (0.73) | NSD2FGBMMP14MAPTMEN1 | |
| SCHEMBL6661851 | 0.89 | MAPT (0.73) | NSD2FGBMMP14MAPTMEN1 | |
| SCHEMBL11688928 | 0.88 | NSD2 (0.66) | NSD2FGBMMP14MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504495-B2 | Quencher compositions comprising anthraquinone moieties | EXIQON A/S (DK) | 2009-03-17 | — | — | US | claimed |
| EP-1538154-B1 | Quencher composition comprising anthraquinone moieties | EXIQON AS (DK) | 2008-12-31 | — | — | EP | claimed |
| EP-1831394-A2 | PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME | Exiqon A/S (DK) | 2007-09-12 | — | — | EP | claimed |
| US-20060166238-A1 | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same | EXIQON A/S (DK) | 2006-07-27 | — | — | US | claimed |
| WO-2006066592-A2 | PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME | EXIQON A/S (DK) | 2006-06-29 | — | — | WO | claimed |
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | QIAGEN GMBH (DE) | 2005-10-13 | — | — | US | claimed |
| EP-1538154-A1 | Quencher composition comprising anthraquinone moieties | Exiqon A/S (DK) | 2005-06-08 | — | — | EP | claimed |
| US-20240209420-A1 | COMPOSITIONS AND METHODS FOR MULTIPLEX DETECTION OF MIRNA AND OTHER POLYNUCELOTIDES | KASA BIO, L.L.C. | 2024-06-27 | — | — | US | disclosed |
| EP-4388133-A2 | COMPOSITIONS AND METHODS FOR MULTIPLEX DETECTION OF MIRNA AND OTHER POLYNUCELOTIDES | Kasa Bio, L.L.C. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11952617-B2 | Methods for multiplex detection of polynucleotides using unbound fluorescent probes and quencher oligonucleotides | KASA BIO, L.L.C. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230265490-A1 | COMPOSITIONS AND METHODS FOR MULTIPLEX DETECTION OF MIRNA AND OTHER POLYNUCLEOTIDES | KASA BIO, L.L.C. | 2023-08-24 | — | — | US | disclosed |
| WO-2023023673-A2 | COMPOSITIONS AND METHODS FOR MULTIPLEX DETECTION OF MIRNA AND OTHER POLYNUCELOTIDES | KASA BIO, L.L.C. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20140227689-A1 | NOVEL METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS | EXIQON A/S (DK) | 2014-08-14 | — | — | US | disclosed |
| EP-1538154-A1 | Quencher composition comprising anthraquinone moieties | Exiqon A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
| US-20050084224-A1 | Colored, radiation-curable compositions | DRAKA COMTEQ B.V. (NL) | 2005-04-21 | — | — | US | disclosed |
| EP-1397408-A1 | COLORED, RADIATION-CURABLE COMPOSITIONS | ALCATEL (FR) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098945-A1 | COLORED, RADIATION-CURABLE COMPOSITIONS | ALCATEL (FR) | 2002-12-12 | — | — | WO | disclosed |
| EP-1023400-B1 | 1,5(8)-BIS(SUBSTITUTED-N-PROPYLAMINO)-4,8(5)-BIS(ARYLTHIO) ANTHRAQUINONE COMPOUNDS | EASTMAN CHEM CO (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-1023400-A1 | 1,5(8)-BIS(SUBSTITUTED-N-PROPYLAMINO)-4,8(5)-BIS(ARYLTHIO) ANTHRAQUINONE COMPOUNDS | EASTMAN CHEMICAL COMPANY (US) | 2000-08-02 | — | — | EP | disclosed |
| WO-1998023689-A1 | 1,5(8)-BIS(SUBSTITUTED-N-PROPYLAMINO)-4,8(5)-BIS(ARYLTHIO) ANTHRAQUINONE COMPOUNDS | EASTMAN CHEMICAL COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | ANXA5, SUN2, ANXA3 | NSD2 3445/4885FGB 2526/4885MMP14 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.